TheraRadar
Clinical-Stage Companies / Stallergenes Greer

Stallergenes Greer

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 9/20/2023

13
Total Trials
7
Phase 3
3
Phase 2
0
Recruiting
138
Score

Pipeline by Phase

Phase 3
7
Phase 2
3
Phase 1
3

Therapeutic Focus

House Dust Mite Allergy Allergic Rhinitis Due to House Dust Mite Asthma Rhinitis, Allergic, Seasonal Allergic Rhinoconjunctivitis

Clinical Trials (13)

NCT05668390 Phase 3 COMPLETED

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma

Started: 9/20/2023

NCT01199133 Phase 3 TERMINATED

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Started: 10/1/2009

NCT02443805 Phase 3 COMPLETED

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Started: 9/29/2015

NCT00803244 Phase 3 COMPLETED

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Started: 1/1/2009

NCT00955825 Phase 3 COMPLETED

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Started: 10/1/2008

NCT01964768 Phase 3 COMPLETED

Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing

Started: 12/1/2010

NCT01731249 Phase 3 COMPLETED

Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis

Started: 11/1/2010

NCT01527188 Phase 2 COMPLETED

Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Started: 12/8/2010

NCT01930461 Phase 2 COMPLETED

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Started: 9/1/2013

NCT00901914 Phase 2 COMPLETED

Study of rBet v1 Tablets

Started: 10/1/2008

NCT01919554 Phase 1 COMPLETED

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

Started: 7/1/2013

NCT01608243 Phase 1 COMPLETED

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Started: 5/1/2012

NCT01224834 Phase 1 COMPLETED

Safety and Tolerability Study of Ragweed SLIT Tablets

Started: 1/1/2009

Drug Candidates

STALORAL® Birch 300 IR 300 IR house dust mites allergen extract tablet Placebo tablet 100 IR house dust mites allergen extract tablet 500 IR house dust mites allergen extract tablet 1000 IR house dust mites allergen extract tablet 1500 IR house dust mites allergen extract tablet 300 IR Placebo SLIT tablets of HDM allergen extracts, 3 different doses (A)
Activity Status: Stale
Last Trial Started: 9/20/2023
Last Trial Ended: 8/6/2025
Trials (12 months): 0
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.